Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

SpringWorks Therapeutics (SWTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ...

Highlights,Financial firms maintain positive ratings for SpringWorks Therapeutics, with price targets reflecting growth ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Willis Towers Watson Public Limited (NASDAQ:WTW). In a filing disclosed on February 11th, the Representative disclosed ...

Julie Hambleton, a director at SpringWorks Therapeutics Inc . (NASDAQ:SWTX), recently sold shares valued at approximately $730,206, according to a recent SEC filing. The transaction involved the sale ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

TD Cowen raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm says ...